Rejected for the 2nd time for the VDPHL01 Clinical Trials (believe it or not!) Chat 3/28/2025
The user was rejected from participating in a clinical trial for an extended-release oral Minoxidil due to having rheumatoid arthritis, despite initially being accepted. They had stopped using Dutasteride and Minoxidil to qualify but continued using other treatments like RU58841 and red light therapy.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity Veradermics VDPHL01 Topline Results for Extended-Release Oral Minoxidil
Extended-release oral minoxidil (VDPHL01) shows promising results for hair growth with improved safety, achieving significant hair count increases and minimal side effects compared to placebo. The treatment is designed to maintain effective concentrations while reducing side effects, making it a safer option for those who cannot tolerate standard minoxidil.
community Following the recent IPO and the positive Phase 3 clinical data for VDPHL01 (extended-release oral minoxidil), what is the projected timeline for the FDA submission and the subsequent commercial availability on the market?
Veradermics' extended-release oral minoxidil is expected to be commercially available in 2027-2028, while another company, Minx, may release a similar product sooner. VDPHL01 is considered more clinically validated compared to Minx.
community Veradermics VDPHL01 Topline Results for Extended-Release Oral Minoxidil
Veradermics is working on FDA approval for extended-release oral Minoxidil. Approval is expected around 2027.
community A minoxidil pill just posted strong phase 3 results. Up to 86% of men improved coverage in six months.
VDPHL01, an extended-release oral minoxidil tablet, showed promising results in improving hair coverage for 79 to 86% of men in a trial, with fewer side effects compared to standard doses. Many users prefer oral minoxidil over topical due to ease of use and fewer side effects, especially for those with pets.
community 30 new hair per cm by extended release minoxidil
Extended-release minoxidil shows promise for hair regrowth, potentially adding 30 new hairs per cm, but concerns about side effects like increased body hair and shortness of breath remain. Users discuss combining it with finasteride or dutasteride for better results, while some express skepticism about it being a complete cure.
Related Research
6 / 6 resultsresearch Comprehensive Review on Hair Loss and Restorative Techniques: Advances in Diagnostic, Artistry, and Surgical Innovation
This review highlights that recent advancements in diagnostics and therapies, including AI-enhanced imaging, biomarker analysis, and novel treatments like low-dose oral minoxidil and JAK inhibitors, are improving the precision and customization of hair loss management.
research Development and Evaluation of a Niosome-Integrated Microneedle System for Targeted Follicular Delivery of Ketoconazole in Alopecia Therapy
This study reports that a novel ketoconazole-loaded microneedle array significantly enhances drug delivery and retention in the skin, demonstrating improved hair growth in animal models, suggesting a promising treatment for androgenic alopecia that addresses current topical therapies' limitations.
research New changes in pregnancy and lactation labelling: Review of dermatologic drugs
This study reviewed and categorized dermatological drugs for pregnancy and lactation according to new FDA labeling guidelines, which replaced simplistic letter categories with detailed information, aiming to improve prescribing decisions by addressing both maternal and paternal reproductive potential.
research “MATH+” Multi-Modal Hospital Treatment Protocol for COVID-19 Infection: Clinical and Scientific Rationale
This review discusses the development of the MATH+ treatment protocol for COVID-19 patients, detailing its scientific and clinical rationale, but reports no new experimental findings.
research The Effects of Lower vs Higher Cell Number of Platelet-Rich Plasma (PRP) on Hair Density and Diameter in Androgenetic Alopecia (AGA): A Randomized, Double-Blinded, Placebo, Parallel-Group Half-Scalp IRB-Approved Study.
This study found that intradermal injections of platelet-rich plasma were equally safe and effective for treating androgenetic alopecia, with higher platelet numbers possibly enhancing hair density and follicle diameter.
research Cannabinoid Compounds as a Pharmacotherapeutic Option for the Treatment of Non-Cancer Skin Diseases
This review examines the role of cannabinoid compounds in treating various skin conditions and suggests their potential as systemic and topical therapies, but it reports no new experimental results.